ArticleEuropean journal of nuclear medicine and molecular imaging2026
¹⁸F-sodium fluoride PET/CT as a complementary measure of osteoblastic disease burden in axial spondyloarthritis: a prospective exploratory study.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeTo determine whether SIJ ¹⁸F-NaF uptake is associated with MRI-defined inflammation and structural damage and whether it provides a complementary measure of osteoblastic disease burden.
methodsIn this prospective exploratory study, 43 adults with chronic low back pain underwent pelvic radiography, sacroiliac joint (SIJ)-MRI, and whole-body ¹⁸F-NaF PET/CT and were classified as having radiographic axial spondyloarthritis or ankylosing spondylitis (AS; n = 29), non-radiographic axial spondyloarthritis (nr-axSpA; n = 5), or degenerative joint disease (DJD; n = 9). MRI was evaluated using SPARCC inflammation and structural scores. SIJ uptake was assessed visually and quantified using SUVmax. The primary endpoint was the correlation between SIJ SUVmax and the SPARCC structural score.
resultsSIJ SUVmax correlated with the SPARCC inflammation (ρ = 0.629) and structural (ρ = 0.606) scores (both p < 0.001) on SIJ-MRI; both associations persisted after mutual adjustment. Median SIJ SUVmax differed across AS, nr-axSpA, and DJD (14.7 [11.2-22.4], 5.5 [4.4-9.9], and 5.7 [4.0-9.2], respectively; p = 0.001). Visually positive uptake occurred in 23/29 (79.3%) patients with AS, including 10/16 without MRI-defined bone marrow edema; no patient with AS had edema without increased uptake. Peripheral joint and entheseal uptake were frequent but non-discriminatory. Exploratory AUCs were 0.841 for AS versus DJD and 0.848 for AS versus nr-axSpA.
conclusionSIJ ¹⁸F-NaF uptake was associated with both MRI-defined inflammation and structural burden in patients with AS, including those without active inflammation on MRI. SIJ SUVmax warrants evaluation as a complementary quantitative imaging biomarker of osteoblastic disease burden, but all derived thresholds require external validation.
Indexed as
Identifiers
42827149What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.